Pfizer, European Pharma Firms Collaborate With European Commission For Future Health Emergency Preparedness
Portfolio Pulse from Vandana Singh
The European Commission has partnered with Pfizer Inc and various European pharmaceutical companies to secure the capacity to produce up to 325 million vaccines annually for potential future global health crises. Pfizer's plants in Ireland and Belgium have been chosen to reserve mRNA vaccine production capacity. The agreement also includes monitoring supply chains and maintaining facilities in a state of readiness. However, concerns have been raised about potential 'vaccine apartheid'.
June 30, 2023 | 6:06 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
BioNTech SE, Pfizer's partner in the development of the COVID-19 vaccine, is not directly involved in this new agreement with the European Commission. However, any impact on Pfizer could indirectly affect BioNTech.
BioNTech is not directly involved in the new agreement between Pfizer and the European Commission. However, as Pfizer's partner in the development of the COVID-19 vaccine, any impact on Pfizer could indirectly affect BioNTech.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Pfizer has partnered with the European Commission to secure the capacity to produce up to 325 million vaccines annually for potential future global health crises. This could potentially increase Pfizer's revenues and strengthen its position in the vaccine market.
The partnership with the European Commission could potentially increase Pfizer's revenues and strengthen its position in the vaccine market. However, the impact will depend on the occurrence of future global health crises and the demand for vaccines.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100